Preclinical work with GLP-1R/GIPR/GcgR triple agonists showed that a balanced triple agonist produced greater body-weight loss than semaglutide, tirzepatide, and dual co-agonists in diet-induced obese mice, reducing weight to near-lean levels at the highest doses
The effect in the 15mg tirzepatide groups was estimated to be a 1.9-2.6% reduction from baseline [9, 10, 11, 12, 13]
Long-Term Health Benefits Beyond weight loss, Semaglutide offers additional health benefits that make it an attractive choice for individuals struggling with obesity
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
However, the product is not intended for direct veterinary administration and must never be used outside approved laboratory environments
Maintaining consistent analytical fingerprints across product versions ensures continued compliance and minimizes regulatory risk throughout the product lifecycle